ELOQUENT-2: A phase III, randomized, open-label trial of lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in relapsed or refractory multiple myeloma (RR MM) (CA204-004).

被引：0
作者：
Lonial, Sagar
Richardson, Paul Gerard Guy
Moreau, Philippe
Orlowski, Robert Z.
San-Miguel, Jesus F.
Dimopoulos, Meletios A.
Palumbo, Antonio Pierangelo
Facon, Thierry
Vij, Ravi
White, Darrell
Reece, Donna Ellen
Singhal, Anil
Kroog, Glenn Scott
Kopit, Justin
Anderson, Kenneth Carl
机构：
[1] Multiple Myeloma Res Consortium, Norwalk, CT USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Hosp, Nantes, France
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Hosp Univ Salamanca, Salamanca, Spain
[7] Hellen Cooperat Oncol Grp, Athens, Greece
[8] Univ Turin, Turin, Italy
[9] Hop Claude Huriez, Lille, France
[10] Washington Univ, Sch Med, St Louis, MO USA
[11] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[12] Princess Margaret Hosp, Program Multiple Myeloma, Toronto, ON M4X 1K9, Canada
[13] Abbott Biotherapeut, Redwood City, CA USA
[14] Bristol Myers Squibb Co, Global Clin Res Oncol, Princeton, NJ USA
[15] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8112
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ELOQUENT-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone (ELd) vs Lenalidomide/Dexamethasone (Ld) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-3-Year Safety and Efficacy Follow-up
    Dimopoulos, M.
    Lonial, S.
    White, D.
    Moreau, P.
    Palumbo, A.
    San Miguel, J.
    Shpilberg, O.
    Anderson, K.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen-Nativ, H.
    Mateos, M. -V
    Belch, A.
    Reece, D.
    Beksac, M.
    Bleickardt, E.
    Poulart, V.
    Katz, J.
    Singhal, A. K.
    Richardson, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 122 - 123
  • [22] Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial
    Ohashi, Kazuteru
    Suzuki, Kenshi
    Sunami, Kazutaka
    Iida, Shinsuke
    Okamoto, Shinichiro
    Handa, Hiroshi
    Matsue, Kosei
    Miyoshi, Masafumi
    Bleickardt, Eric
    Matsumoto, Morio
    Taniwaki, Masafumi
    BLOOD, 2016, 128 (22)
  • [23] Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study
    Cella, David
    McKendrick, Jan
    Davis, Harrison
    Vij, Ravi
    Chen, Clara
    BLOOD, 2019, 134
  • [24] PHASE 3 ELOQUENT-2 STUDY: EXTENDED 4-YEAR FOLLOW-UP OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M. A.
    Lonial, S.
    White, D.
    Moreau, P.
    Mateos, M. -V.
    San Miguel, J.
    Anderson, K. C.
    Shpilberg, O.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen, H.
    Belch, A.
    Reece, D. E.
    Beksac, M.
    Mekan, S.
    Sy, O.
    Singhal, A. K.
    Richardson, P. G.
    Weisel, K.
    HAEMATOLOGICA, 2017, 102 : 167 - 168
  • [25] Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)
    Derman, Ben A.
    Kubicki, Tadeusz
    Simmons, Heidi
    Afrough, Aimaz
    Zonder, Jeffrey A.
    Grinblatt, David L.
    Anderson, Larry D., Jr.
    Kin, Andrew
    Narula, Sunil
    Rayani, Shayan
    Gurbuxani, Sandeep
    Karrison, Theodore
    Jiang, Ken
    Major, Ajay
    Cooperrider, Jennifer H.
    Jacob, Allison P.
    Jakubowiak, Andrzej J.
    BLOOD, 2023, 142
  • [26] CheckMate 602: An open-label, randomized, phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
    Lonial, Sagar
    Richardson, Paul G.
    Reece, Donna Ellen
    Mohamed, Hesham
    Shelat, Suresh
    Miguel, Jesus San
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
    Kohmei Kubo
    Mitsuo Hori
    Kensuke Ohta
    Hiroshi Handa
    Kiyohiko Hatake
    Morio Matsumoto
    Shotaro Hagiwara
    Kazuteru Ohashi
    Chiaki Nakaseko
    Kenshi Suzuki
    Shigeki Ito
    Gen Kinoshita
    Suresh G. Shelat
    Masafumi Miyoshi
    Naoki Takezako
    International Journal of Hematology, 2020, 111 : 65 - 74
  • [28] Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
    Jacob P. Laubach
    Sascha A. Tuchman
    Jacalyn M. Rosenblatt
    Constantine S. Mitsiades
    Kathleen Colson
    Kelly Masone
    Diane Warren
    Robert A. Redd
    Dena Grayson
    Paul G. Richardson
    Blood Cancer Journal, 11
  • [29] Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
    Kubo, Kohmei
    Hori, Mitsuo
    Ohta, Kensuke
    Handa, Hiroshi
    Hatake, Kiyohiko
    Matsumoto, Morio
    Hagiwara, Shotaro
    Ohashi, Kazuteru
    Nakaseko, Chiaki
    Suzuki, Kenshi
    Ito, Shigeki
    Kinoshita, Gen
    Shelat, Suresh G.
    Miyoshi, Masafumi
    Takezako, Naoki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (01) : 65 - 74
  • [30] Durable progression-free survival benefit in early responders to elotuzumab plus lenalidomide and dexamethasone (ELd): analysis of ELOQUENT-2 4-year data in relapsed/refractory (RR) multiple myeloma (MM)
    Scheid, C.
    Roellig, C.
    Weisel, K.
    Salwender, H-J
    Gramatzki, M.
    Edmaier-Schroeger, K.
    Sy, O.
    Goldschmidt, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 189 - 189
12345